| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-998 | |
| Phytochemical name or plant extracts | Methyl β-lilacinobioside | |
| PMID | 30591807 | |
| Literature evidence | The side effects of the drug as well as the radiotherapy used for the treatment of cancer is severe, therefore, the search of the natural products from the sources of wild plants having anticancer potential is become immense importance today. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Glycoside | |
| Source of phytochemicals or plant Extracts | Caralluma retrospiciens | |
| Geographical availability | Algeria, Burkina, Chad, Djibouti, Eritrea, Ethiopia, Ghana, Kenya, Mali, Mauritania, Morocco, Niger, Nigeria, Oman, Saudi Arabia, Senegal, Somalia, Sudan, Uganda, Yemen | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | topo II | |
| Gene or Protein evidence | Based on a small-scale computational target screening, Topoisomerase II was identified as the potential binding target of methyl β-lilacinobioside. | |
| Target pathways | NA | |
| IC50 | NA | |
| Potency | NA | |
| Cell line/ mice model | MCF-7 | |
| Additional information | NA | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:95345-1 | |
| Safety | NA |